Clinical trials: Neoplasm, Oral
Neoplasms, NUT Carcinoma
BI 894999 First in Human Dose Finding Study in Advanced Malignancies
This study is open to adults with different types of advanced cancer (solid tumours). The study is also open to patients with diffuse large B-cell lymphoma in whom previous treatment was not successful.
- Trial name
- NCT02516553
- Testing
- BI 894999
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 174 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
CONTESSA 2 is a multinational, multicenter, Phase 2 study of tesetaxel in patients with HER2 negative, HR positive, locally advanced or metastatic breast cancer (LA/MBC) not previously treated with a taxane.
- Trial name
- CONTESSA 2 (NCT03858972)
- Testing
- Tesetaxel, Capecitabine
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 152 people
- Sponsor
- Odonate Therapeutics, Inc.
Solid Tumours
To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Study to assess the effect of Itraconazole and Fluconazole on the pharmacokinetics of Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Male Volunteers
- Trial name
- NCT02093728
- Testing
- selumetinib, itraconazole, fluconazole
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Prostate Cancer
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, topotecan, and estramustine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084565
- Testing
- estramustine phosphate sodium, paclitaxel, topotecan hydrochloride
- Sponsor
- Fox Chase Cancer Center
Oral Cancer
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions
Evaluation of the metformin drug effect as a drug that found to improve the quality of tissues, decrease signs \& symptoms of cancer, and decrease histo-pathological criteria of dysplasia.
- Trial name
- NCT03684707
- Testing
- Metformin Hcl 500Mg 24Hr Sa Tab, starch tablet
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Multiple Myeloma and Plasma Cell Neoplasm
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00477971
- Testing
- filgrastim, dexamethasone, melphalan
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Mayo Clinic
Advanced Solid Tumor, Lymphomas
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
LEE011 is a new oral drug designed to inhibit the activity of an enzyme known as CDK4/6. CDK4/6 is involved in the process that allows both normal and cancer cells to divide and multiply.
- Trial name
- NCT01237236
- Testing
- LEE011
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 156 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
This study will assess the pharmacokinetics of nilotinib in Ph+ CML pediatric patients that are newly diagnosed or resistant or intolerant to imatinib or dasatinib or refractory or relapsed Ph+ ALL compared to the adult…
- Trial name
- NCT01077544
- Testing
- Nilotinib
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Anal, Colon, and Rectal Cancers, Head and Neck Cancer
Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
Cetuximab, erlotinib, and panitumumab are all recently FDA approved epidermal growth factor receptor (EGFR) inhibitors that treat a wide variety of tumor types, such as colon, lung, and head and neck.
- Conditions
- Anal, Colon, and Rectal Cancers, Head and Neck Cancer, Lung Cancer, Colon Cancer
- Trial name
- NCT01137162
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Breast Neoplasm
Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer
The primary purpose of the study is to examine the safety and effectiveness of combination therapy consisting of daily oral capecitabine and weekly intravenous vinorelbine in stage IV breast cancer subjects.
- Trial name
- NCT00194727
- Testing
- Vinorelbine, Capecitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Oral Neoplasm, Pharynx Cancer
Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy
The investigators compare the ease of intubation between a new ultra-thin endotracheal tube, "Tritube", and a standard endotracheal tube in patients with predictors of difficult laryngoscopy.
- Conditions
- Oral Neoplasm, Pharynx Cancer, Larynx Cancer
- Trial name
- Tritube (NCT03653039)
- Testing
- Tritube, Standard enditracheal tube
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Michael Seltz Kristensen
Myeloma
Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma
An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients with Advanced Multiple Myeloma.
- Trial name
- NCT00242827
- Testing
- Oral CEP-701
- Where
- 5 sites in United States
- Sponsor
- Cephalon
Glioblastoma Multiforme (GBM), Glioblastoma
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly…
- Conditions
- Glioblastoma Multiforme (GBM), Glioblastoma, Glioma of Brain, Glioblastoma, Adult
- Trial name
- CAPTEM (NCT03213002)
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Northwell Health
Neoplasms, Prostatic Neoplasms, Castration-Resistant
HTL0039732 in Participants With Advanced Solid Tumours
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with…
- Conditions
- Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms
- Trial name
- NCT05944237
- Testing
- HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion
- Where
- 6 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cancer Research UK
Ovarian Cancer, Cancer of Ovary
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
The purpose of this study is to determine the effectiveness of fenretinide (4-HPR/LXS) plus ketoconazole in the treatment of recurrent ovarian cancer or primary peritoneal carcinoma.
- Conditions
- Ovarian Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasms
- Trial name
- NCT01535157
- Testing
- Fenretinide/LXS + Ketoconazole
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- South Plains Oncology Consortium
Head and Neck Cancer, Lung Cancer
Subcutaneous Amifostine Safety Study
Amifostine is a radioprotective drug which is approved by the US FDA for administration prior to each radiation treatment using the intravenous route. The study evaluated the safety of amifostine administered subcutaneously.
- Conditions
- Head and Neck Cancer, Lung Cancer, Lymphoma
- Trial name
- NCT00158041
- Testing
- Amifostine administered subcutaneously
- Where
- United States
- Volunteers
- 452 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Head and Neck Cancer
Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Gene therapy may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have advanced head…
- Trial name
- NCT00009841
- Testing
- EGFR antisense DNA, growth factor antagonist therapy, DC-cholesterol liposome
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Pittsburgh
Leukemia, Myeloid, Acute
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
This is a 2-part, open-label, interventional study conducted in approximately 42 subjects with AML harboring an IDH2 mutation. The overall study is a 3-arm investigation of the PK effects of enasidenib at steady state on the…
- Trial name
- NCT03720366
- Testing
- enasidenib, Arm 1 probes, Arm 2 Probes
- Where
- 10 sites in Australia, South Korea
- Volunteers
- 40 people
- Sponsor
- Celgene
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
This randomized trial studies transdermal or oral telapristone acetate in treating patients undergoing surgery to remove the breast (mastectomy).
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma In Situ, Lobular Breast Carcinoma In Situ
- Trial name
- NCT02314156
- Testing
- Telapristone Acetate, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Northwestern University
Grade IV Astrocytoma, Glioblastoma
Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma
O6-méthylguanine méthyltransférase (MGMT) is the main repair gene after DNA lesion induced by Temozolomide in combination with radiation therapy of Glioblastoma (GBM) in Stupp.R et al published regimen.
- Trial name
- FOLAGLI (NCT01700569)
- Testing
- Temozolomide, folinic acid at pharmacological dose is the escalated drug, High voltage radiation therapy (linear accelerator)
- Where
- 4 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut Cancerologie de l'Ouest
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.